Entries by surrozen

Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies

–Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regeneration– –Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing– –Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing– South San Francisco (CA), […]

Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials

— IND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease — SOUTH SAN FRANCISCO, Calif., June 19th, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful completion of a $50 million Series C financing. Investors from the Series B financing participated […]

Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

— Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online  — SOUTH SAN FRANCISCO, Calif., May 4, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced today that two abstracts were published on the 2020 Digestive Disease Week (DDW) site. These abstracts were […]

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

—Award recognizes Dr. Nusse’s seminal contributions to elucidating the mechanism and role of Wnt signaling— SOUTH SAN FRANCISCO, Calif., April 6, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that one of its scientific founders, Dr. Roel Nusse, received the 2020 Canada Gairdner International Award for […]

Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology

— Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies — SOUTH SAN FRANCISCO, Calif., March 30, 2020 — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced a peer-reviewed publication describing its novel platform for generation of potent and selective Wnt-mimetics. The article, “Development of Potent, […]

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 2, 2020 – Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues, today announced that President & Chief Executive Officer, Craig Parker, will present at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts. The presentation will begin at 10:30 a.m. […]

Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the appointment of Trudy Vanhove, MD, PhD, MBA, as Chief Medical Officer. An experienced biopharmaceutical executive, Dr. Vanhove brings to […]

Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates

— Anna Berkenblit, MD, appointed to Surrozen Board of Directors — SAN FRANCISCO, March 14, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the successful completion of a $50 million Series B financing. The […]

Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder

SAN FRANCISCO, April 4, 2018 /PRNewswire/ — Surrozen, a preclinical-stage company advancing drug candidates that promote the repair and regeneration of human tissues, today announced two appointments to expand its leadership team.  Craig Parker, a biotech industry veteran recently of Jazz Pharmaceuticals, has been appointed CEO, and Hans Clevers, M.D., Ph.D., professor of molecular genetics at the Hubrecht Institute, […]